|
http://www.cypressbio.com/corp/health/
milbackground.jsp
|
Cypress Bioscience, Inc.recently completed a Phase II clinical trial evaluating
the first NSRI, milnacipran, as an oral treatment for FMS. In this study,
milnacipran was shown to statistically improve a number of primary and secondary
hallmark symptoms of fibromyalgia.
|